Induction with Taxane/Platinum Based/5-Fu (TPF) Chemotherapy as a Predictor of Response to Definitive Concurrent Chemo Radiotherapy (CCRT) in Locally Advanced Inoperable Head and Neck Cancers
DOI:
https://doi.org/10.51253/pafmj.v74i6.6133Keywords:
Chemoradiotherapy, Head and Neck Carcinomas, Induction Chemotherapy, Squamous Cell Carcinoma of Head and Neck.Abstract
Objective: To evaluate the effect of induction with Taxane/platinum based/5-FU chemotherapy as a predictor of response to definitive concurrent chemoradiotherapy in inoperable locally advanced squamous cell carcinoma of head and neck.
Study Design: Interventional study.
Place and Duration of Study: Medical Oncology Department, Jinnah Postgraduate Medical Center Karachi, Pakistan, from Oct 2019 to Oct 2020.
Methodology: A total of 71 patients aged 18 years or more with inoperable, locally advanced squamous cell carcinoma of the head and neck were included. Patients were given three cycles of induction therapy with injection Docetaxel 75 mg/m2 day 01, injection Cisplatin 75 mg/m2 intravenously (IV) day 01 and 5-Fluorouracil 1000 mg/m2 IV day one-four every three weeks. CT scan was repeated after the last cycle to check response. All patients irrespective of response to induction received concurrent chemoradiotherapy, which included administration of weekly Carboplatin AUC-2 with radiotherapy 5 days per week. Response was assessed according to revised Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria.
Results: The mean age of our respondents was 48.46±12.74 years. Of 71 patients, 26(36.6%) had achieved partial response after concurrent chemoradiotherapy, 24(33.8%) had achieved complete response, 10(14.1%) had stable disease and 11(15.5%) had progressive disease. There was a statistically significant association between response to concurrent chemoradiotherapy and response to induction chemotherapy (p=0.001).
Conclusion: The response of induction chemotherapy can be used as a guide to select patients for definitive concurrent chemoradiotherapy versus palliative treatment.
Downloads
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
https://doi.org/10.3322/caac.21492
Vigneswaran N, Williams MD. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am 2014; 26(2): 123-141.
https://doi.org/10.1016/j.coms.2014.01.001
Lowe NM, Bernstein JM, Mais K, Garcez K, Lee LW, Sykes A, et al. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status. J Cancer Res Clin Oncol 2018; 144(2): 389-401.
https://doi.org/10.1007/s00432-017-2553-9
Nouman M, Haider G, Bukhari N, Yousuf A, Nouman R, Shaikh MR, et al. Response Rate of Cisplatin Plus Docetaxel as Primary Treatment in Locally Advanced Head and Neck Carcinoma (Squamous Cell Types). Asian Pac J Cancer Prev 2020; 21(3): 825-830.
https://doi.org/10.31557/APJCP.2020.21.3.825
Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codecà C, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol 2017; 28(9): 2206-2212.
https://doi.org/10.1093/annonc/mdx299
Pignon JP, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92(1): 4-14.
https://doi.org/10.1016/j.radonc.2009.04.014
Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Cruz Hernandez JJ, et al. Taxane-Cisplatin-Fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 2013; 31(23): 2854-2860.
https://doi.org/10.1200/JCO.2012.47.7802
Tousif D, Sarathy V, Kumar R, Naik R. Randomized Controlled Study Comparing Efficacy and Toxicity of Weekly vs. 3-Weekly Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. Front Oncol 2020; 10: 1284.
https://doi.org/10.3389/fonc.2020.01284
Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 2010; 195(2): 281-289.
https://doi.org/10.2214/AJR.09.4110
Prestwich RJ, Öksüz D, Dyker K, Coyle C, Şen M. Feasibility and efficacy of induction Docetaxel , Cisplatin, and 5-Fluorouracil chemotherapy combined with Cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2011; 81(4): e237-243.
https://doi.org/10.1016/j.ijrobp.2011.03.043
Haddad RI, Posner M, Hitt R, Cohen EEW, Schulten J, Lefebvre JL, et al. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol 2018; 29(5): 1130-1140.
https://doi.org/10.1093/annonc/mdy102
Ahn JS, Cho SH, Kim OK, Lee JK, Yang DH, Kim YK, et al. The efficacy of an induction chemotherapy combination with Docetaxel , Cisplatin, and 5-FU followed by concurrent chemoradiotherapy in advanced head and neck cancer. Cancer Res Treat 2007; 39(3): 93-98.
https://doi.org/10.4143/crt.2007.39.3.93
Choudhury H, Gorain B, Pandey M, Kumbhar SA, Tekade RK, Iyer AK, et al. Recent advances in TPGS-based nanoparticles of Docetaxel for improved chemotherapy. Int J Pharm 2017; 529(1-2): 506-522.
https://doi.org/10.1016/j.ijpharm.2017.07.018
Kiong KL, de Souza NN, Sultana R, Iyer NG. Meta-analysis of induction chemotherapy as a selection marker for chemoradiation in the head and neck. Laryngoscope 2018; 128(7): 1594-1601.
https://doi.org/10.1002/lary.27011
Karabajakian A, Gau M, Reverdy T, Neidhardt EM, Fayette J. Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of Belief. Cancers 2018; 11(1): 15.
https://doi.org/10.3390/cancers11010015
Ferrari D, Ghi MG, Franzese C, Codecà C, Gau M, Fayette J. The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality. Front Oncol 2020; 10: 7.
https://doi.org/10.3389/fonc.2020.00007
Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 2014; 32(25): 2735-2743.
https://doi.org/10.1200/JCO.2013.54.6309
Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen F, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004; 15(8): 1179-1186.
https://doi.org/10.1093/annonc/mdh308
Ma J, Liu Y, Huang XL, Zhang ZY, Myers JN, Neskey DM, et al. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis. Oral Oncol 2012; 48(11): 1076-1084.
https://doi.org/10.1016/j.oraloncology.2012.06.014
Mizumachi T, Homma A, Kakizaki T, Sakashita T, Kano S, Hatakeyama H, et al. Feasibility and efficacy of induction Docetaxel , Cisplatin, and 5-Fluorouracil chemotherapy combined with concurrent weekly Cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma. Int J Clin Oncol 2015; 20(3): 431-437.
https://doi.org/10.1007/s10147-014-0726-y
Paccagnella A, Ghi MG, Loreggian L, Buffoli A, Koussis H, Mione CA, et al. Concomitant chemoradiotherapy versus induction Docetaxel , Cisplatin and 5 Fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010; 21(7): 1515-1522.
https://doi.org/10.1093/annonc/mdp573
Wang HM, Lin CY, Hsieh CH, Hsu CL, Fan KH, Chang JT, et al. Induction chemotherapy with dose-modified Docetaxel, Cisplatin, and 5-Fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer. J Formos Med Assoc 2017; 116(3): 185-192.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Batool Aslam Memon, Ghulam Haider, Tooba Ather, Maliha Ashfaq, Muhammad Aslam, Sana Sehar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
